COVID-19 Vaccine: The Path to Development
Since January 2020, when China shared the whole genome sequence, researchers have been working tirelessly to create a potential vaccine.
All articles by Steve Duffy
Zoonotic Diseases: How COVID-19 Could Alter Our Preparedness for Future Pandemics
The impact of COVID-19 on the global health system and economy will likely result in large-scale changes in zoonotic disease prevention preparedness.
Haymarket Medical Network Joins Ad Council Private Marketplace
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
Exebacase Gains Breakthrough Therapy Status for MRSA Bacteremia, Including Right-Sided Endocarditis
Exebacase is a novel, recombinantly-produced lysin (cell wall hydrolase enzyme), that targets the peptidoglycan cell wall.
Investigational Antibiotic Gets Orphan Drug Status for Pulmonary Exacerbations of Cystic Fibrosis
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
Vaccine to Prevent Ricin Intoxication Gets Fast Track Status
The FDA has granted Fast Track designation to RiVax® for the prevention of ricin intoxication.
Recarbrio Gets Priority Review for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
The FDA has accepted for review a sNDA for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Influenza Vaccine for Older Adults Granted Fast Track Status
The Food and Drug Administration has granted Fast Track designation to NanoFlu (Novavax) for seasonal influenza vaccination in adults ≥65 years.
Haymarket Medical Education Receives Interprofessional Joint Accreditation for the Healthcare Team
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
Renal Impairment Labeling Updates for Sofosbuvir-Based HCV Therapies
The FDA has approved updated labeling for Epclusa, Harvoni and Vosevi to include updated information regarding treatment of patients with HCV who have severe renal impairment including those with end stage renal disease who are on dialysis.
-
Loading...
-
Loading...
Next post in Hepatitis
